Vyro Biotherapeutics

Vyro Biotherapeutics is a Brazilian biotechnology company pioneering the use of oncolytic viruses to treat aggressive central nervous system tumors. The company leverages the natural tropism of the Zika virus for neural progenitor cells to selectively target and eliminate cancer stem cells in glioblastoma and medulloblastoma. By engineering specific strains of the virus, Vyro aims to provide a potent therapeutic option for cancers that are currently resistant to standard treatments. Their approach combines virotherapy with immunotherapy to stimulate a systemic anti-tumor response. The company is currently advancing its lead programs through pre-clinical development toward first-in-human clinical trials. Vyro was founded as a spin-off from the University of São Paulo and is supported by prominent Brazilian venture capital and healthcare institutions.